Use of Clarithromycin in Mustard-Induced Bronchiolitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We looked for the effectiveness of low-dose long-term prescription of clarithromycin in mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

NCT03093974

Non Cystic Fibrosis Bronchiectasis

COMPLETED PHASE3

Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD

NCT00147667

COPD

UNKNOWN PHASE2/PHASE3

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

NCT01332097

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians

NCT03859414

Asthma Chronic Obstructive Pulmonary Disease

COMPLETED PHASE1

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis

NCT01769898

Bronchiectasis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiolitis Obliterans Acute Obliterating Bronchiolitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clarithromycin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* His/her own will to participate
* Documented chemical exposure
* Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)

Exclusion Criteria

* any drug reactions during the trial
* history of sensitivity to macrolides
* diarrhea, gray stool, jaundice, eosinophilia, acute cholestatic hepatitis, pruritis, dark urine, abdominal pain, osteomatosis, depression, taste change, behavioural changes, early fatigue, odynophagia, glossitis , dizziness
* co-adminstration of: terfenadine, theophylline, carbamazepine, ergotamine, dihydroergotamine, warfarin, cisapride, digoxin, triazolam, phenytoin, steroids, any immunosuppressive, any systemic antibiotics
* using drugs that he/she cannot discontinue
* using drugs with potential interaction
* subject will to exit from the trial
* history of lobe resection of lung
* history of exacerbation in the last month prior to the beginning of trial
* continuous need to oxygen
* use of corticosteroids in last week prior to the trial beginning
* Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
* exacerbating of subjects
* creatinine srum level more than normal
* increasing ALT, AST levels
* total bilirubin more twice than normal
* subjects who did not use their drugs properly

Eligible Sex

MALE

Accepts Healthy Volunteers

No